News

Baxalta develops, manufactures and commercializes therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. The acquisition is expected to double Shire’s annual revenues to $20bn

Orphan Drug Designation by the FDA provides regulatory and financial incentives to develop therapies for life-threatening or chronically debilitating conditions affecting fewer than 200 000 people in the

The Bioreactor 3PACK configuration consists of three 2,000L single-use production bioreactors and associated seed train for scale up, allowing for flexible production with scales from 2,000L to 6,000L

These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aß), which are widely believed to play

The Android-exclusive app, available from the Google Play Store, was developed by Alzheimer’s Research UK and virtual reality specialists VISYON, and uses the widely-available Google Cardboard headset to

The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in

The study will explore if novel CIIE-identified targets, when formulated in the DepoVax delivery system, provide immunogenic responses against parasites that cause life-threatening malaria. The collaborators expect to

ARIAD transferred all rights to its EU operations to Incyte, which has acquired all shares of ARIAD Pharmaceuticals (Luxembourg) S.a.r.l., the parent company of ARIAD’s European subsidiaries responsible

The guidance is expected to take 3-4 months pending the response from the MHRA in the UK. Under a European system called the "Decentralized Procedure" (DCP), a company